A randomized, open-label, multicenter study of switching to brolucizumab with or without a loading dose for patients with suboptimal anatomically controlled neovascular age-related macular degeneration-the FALCON study

F G Holz, Steffen Schmitz-Valckenberg, A Wolf, H Agostini, K Lorenz, A Pielen, N Feltgen, R Guthoff, C Quiering, A Clemens, K Jaeger, F G Holz, Steffen Schmitz-Valckenberg, A Wolf, H Agostini, K Lorenz, A Pielen, N Feltgen, R Guthoff, C Quiering, A Clemens, K Jaeger

Abstract

Background: Treatment initiation with brolucizumab, a new potent anti-vascular endothelial growth factor (VEGF) agent, is typically performed with three monthly injections (loading dose) and has been well studied in treatment-naïve patients. However, no clinical data are available yet on whether or not anti-VEGF pretreated patients also benefit from a loading dose. In the clinical setting, different heterogeneous treatment patterns are used as no clinical trial has addressed this so far in a head-to-head comparison. Therefore, the FALCON study is investigating whether patients with unsatisfactory response to previous anti-VEGF treatments benefit from a loading dose at the switch to brolucizumab treatment.

Methods: FALCON is a 52-week, two-arm, randomized, open-label, multicenter, multinational study in patients with residually active neovascular age-related macular degeneration (nAMD) who will be randomized 1:1 and started with brolucizumab 6 mg loading (three monthly loading doses) or brolucizumab 6 mg non-loading (one initial injection) and consecutive treatment every 12 weeks, respectively. The primary objective is to demonstrate non-inferiority of the non-loading vs. loading arm in mean change of best-corrected visual acuity (BCVA) from baseline to the mean value at week 40 to week 52. Secondary objectives include the assessment of anatomical outcomes, treatment intervals, safety and tolerability.

Results: FALCON will be the first study to assess treatment initiation with an anti-VEGF agent in a switch situation with or without loading dose in patients with nAMD.

Conclusions: The results will support the optimization of treatment of patients with previous unsatisfactory anti-VEGF response. Therefore, we expect to see an impact on current clinical practice which has been established for more than a decade.

Trial registration: Clinicaltrials.gov: NCT04679935, date of registration-22-Dec 2020; EUDRACT number: 2019-004763-53, date of registration-03 Dec 2019.

Keywords: Anti-VEGF; Brolucizumab; Neovascular age-related macular degeneration; Switch.

Conflict of interest statement

FH, SS, AW, KL, AP, NF and RG received investigator fees from Novartis. AC is full time employee and shareholder of Novartis Pharma AG. CQ and KJ are full-time employees of Novartis Pharma GmbH.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Study design of FALCON. BCVA best corrected visual acuity, EOS end of the study, q8w 8-week dosing interval

References

    1. Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e106–116. doi: 10.1016/S2214-109X(13)70145-1.
    1. Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in denmark: year 2000 to 2010. Am J Ophthalmol. 2012;153(209–213):e202. doi: 10.1016/j.ajo.2011.10.016.
    1. Campbell JP, Bressler SB, Bressler NM. Impact of availability of anti-vascular endothelial growth factor therapy on visual impairment and blindness due to neovascular age-related macular degeneration. Arch Ophthalmol. 2012;130:794–795. doi: 10.1001/archophthalmol.2011.2480.
    1. Holz FG, Schmitz-Valckenberg S, Fleckenstein M. Recent developments in the treatment of age-related macular degeneration. J Clin Invest. 2014;124:1430–1438. doi: 10.1172/JCI71029.
    1. Hussain RM, Ciulla TA. Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration. Expert Opin Emerg Drugs. 2017;22:235–246. doi: 10.1080/14728214.2017.1362390.
    1. Gaudreault J, Gunde T, Floyd HS, Ellis J, Tietz J, Binggeli D, Keller B, Schmidt A, Escher D. Preclinical pharmacology and safety of ESBA1008, a single-chain antibody fragment, investigated as potential treatment for age related macular degeneration. Invest Ophth Vis Sci. 2012;53:3025–3025.
    1. Tietz J, Spohn G, Schmid G, Konrad J, Jampen S, Maurer P, Schmidt A, Escher D. Affinity and potency of RTH258 (ESBA1008), a novel inhibitor of vascular endothelial growth factor A for the treatment of retinal disorders. Invest Ophthalmol Vis Sci. 2015;56:1501.
    1. Tadayoni R, Sararols L, Weissgerber G, Verma R, Clemens A, Holz FG. Brolucizumab: a newly developed anti-VEGF molecule for the treatment of neovascular age-related macular degeneration. Ophthalmologica. 2020 doi: 10.1159/000513048.
    1. Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, Gomes AV, Warburton J, Weichselberger A, Holz FG, Hawk IHS. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127:72–84. doi: 10.1016/j.ophtha.2019.04.017.
    1. Dugel PU, Singh RP, Koh A, Ogura Y, Weissgerber G, Gedif K, Jaffe GJ, Tadayoni R, Schmidt-Erfurth U, Holz FG. HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2021;128:89–99. doi: 10.1016/j.ophtha.2020.06.028.
    1. Baumal CR, Bodaghi B, Singer M, Tanzer DJ, Seres A, Joshi MR, Feltgen N, Gale R. Expert opinion on management of intraocular inflammation, retinal vasculitis, and vascular occlusion after brolucizumab treatment. Ophthalmol Retina. 2020 doi: 10.1016/j.oret.2020.09.020.
    1. Holz FG, Heinz C, Wolf A, Hoerauf H, Pleyer U. Intraocular inflammation with brolucizumab use: patient management-diagnosis-therapy. Ophthalmologe. 2021;118:248–256. doi: 10.1007/s00347-021-01321-8.
    1. Wykoff CC, Clark WL, Nielsen JS, Brill JV, Greene LS, Heggen CL. Optimizing Anti-VEGF treatment outcomes for patients with neovascular age-related macular degeneration. J Manag Care Spec Pharm. 2018;24:S3–S15. doi: 10.18553/jmcp.2018.24.2-a.s3.
    1. Gale RP, Pearce I, Eter N, Ghanchi F, Holz FG, Schmitz-Valckenberg S, Balaskas K, Burton BJL, Downes SM, Eleftheriadis H, George S, Gilmour D, Hamilton R, Lotery AJ, Patel N, Prakash P, Santiago C, Thomas S, Varma D, Walters G, Williams M, Wolf A, Zakri RH, Igwe F, Ayan F. Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study. Br J Ophthalmol. 2020;104:493–499. doi: 10.1136/bjophthalmol-2019-314251.
    1. Pikkel J, Attas S. “What should I inject next?” Challenging treatment decisions in the multiple anti-VEGF: a review of publications exploring anti-VEGF switching for nAMD. Int Ophthalmol. 2018;38:2031–2039. doi: 10.1007/s10792-017-0695-z.
    1. Seguin-Greenstein S, Lightman S, Tomkins-Netzer O. A meta-analysis of studies evaluating visual and anatomical outcomes in patients with treatment resistant neovascular age-related macular degeneration following switching to treatment with aflibercept. J Ophthalmol. 2016;2016:4095852. doi: 10.1155/2016/4095852.
    1. Marquis LM, Mantel I. Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2020;258:1591–1596. doi: 10.1007/s00417-020-04730-8.
    1. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, Group MS Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–1431. doi: 10.1056/NEJMoa054481.
    1. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U, View, Groups VS Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537–2548. doi: 10.1016/j.ophtha.2012.09.006.
    1. Sagkriotis A, Chakravarthy U, Griner R, Doyle O, Wintermantel T, Clemens A. Application of machine learning methods to bridge the gap between non-interventional studies and randomized controlled trials in ophthalmic patients with neovascular age-related macular degeneration. Contemp Clin Trials. 2021;104:106364. doi: 10.1016/j.cct.2021.106364.
    1. Kodjikian L, Parravano M, Clemens A, Dolz-Marco R, Holz FG, Munk MR, Nicolo M, Ricci F, Silva R, Talks SJ, Verma RK, Zarranz-Ventura J, Zweifel SA. Fluid as a critical biomarker in neovascular age-related macular degeneration management: literature review and consensus recommendations. Eye (Lond) 2021 doi: 10.1038/s41433-021-01487-0.
    1. Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y, Investigators A. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: A Randomized Controlled Trial. Adv Ther. 2020;37:1173–1187. doi: 10.1007/s12325-020-01236-x.
    1. Silva R, Berta A, Larsen M, Macfadden W, Feller C, Mones J, Group TS. Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND study. Ophthalmology. 2018;125:57–65. doi: 10.1016/j.ophtha.2017.07.014.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe